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Discoveries of restriction enzymes by Hamilton Smith and
Daniel Nathans [1], and reverse transcriptase by Howard
Temin [2] and David Baltimore [3] in the 1970s set the
stage for an explosion in molecular and clinical genetics.
Armed with a sufficient amount of the mRNA product of a
gene such as the beta globin gene, investigators could now
produce a radioactive DNA copy (cDNA) of the mRNA and
use it as a valuable probe of gene expression. Moreover, the
globin cDNA was functional. Cloned into an expression
plasmid [4] and transduced into an appropriate cell, the
cDNA would produce mature beta globin mRNA, and
cDNAs could be manipulated at will in what became the
era of recombinant DNA technology.
The new discoveries were greeted with enthusiasm by most
biologists and clinical investigators but with mounting
horror and suspicion by many members of the public and
their elected officials, as well as some academics.
Frankensteins were thought to be loose in biomedical
laboratories; monsters would be created; plagues of vicious
E. coli would be loosed on an innocent population; mad
scientists would forever contaminate the food supply; the
new genetics would lead to a resurgence of social
Darwinism. The specter of Nazi medicine roiled some
faculty meetings and communities in which the science was
rapidly advancing. Rules and restrictions were demanded
that would deliberately inhibit the work. To their credit,
leaders of this new genetics revolution met in Asilomar
California [5], where they established laboratory standards
intended to reassure themselves, their colleagues, and the
general population that gene manipulation could be
rendered safe and useful.
While eager clinical investigators hoped to apply the new
genetics in the treatment of inherited diseases, cooler
heads recognized that the technology was not sufficiently
powerful or predictable. The more cautious advised the
National Institutes of Health to be very wary of human
application because the biological 'rules of the game' had
not yet been established. That did not stop an American
clinical entrepreneur from injecting beta globin cDNA into
the bone marrows of thalassemic patients in Italy and
Israel. His reward was failure and opprobrium [6], and
academic medicine encountered a Congress increasingly
determined to surround clinical research with an ever-
growing net of regulation.
Following the unfortunate thalassemia contretemps,
scientists focused on a fundamental problem. How could a
cDNA be introduced efficiently into a rare, quiescent,
mammalian cell, such as a bone marrow stem cell, remain
potentially active, and be sufficiently expressed when that
stem cell developed into a hematopoietic precursor and
subsequently fully differentiated functional blood cell?
Furthermore, could a defective gene be actually replaced in
human cells in a targeted fashion by a normal counterpart
and still maintain high transcription efficiency [7], or
would such 'plug and socket' technology be so inefficient
that correction would be impossible? Instead, could cDNAs
such as a beta globin cDNA be carried into the target cell
chromosomes on the back of a virus, such as a retrovirus,
and could the transduced sequence express its mature
mRNA regardless of its genomic location?The idea of a retrovirus as a gene-transfer agent was first
seen as dangerously oncogenic, until 1983 and 1984 when
Mann, Mulligan and Baltimore [8] devised cell lines that
would produce replication-defective retroviruses that still
exploited the capacity of the viruses to incorporate
themselves efficiently in the DNA of dividing cells. For the
most part, the modified retroviral vectors infected human
cells at comfortingly low multiplicities of infection.
Shortly after this, Williams and Mulligan [9] and Dick and
Bernstein [10], and their colleagues, showed that murine
bone marrow cells could be transduced with defective
retroviruses carrying cDNAs, and that mature nucleated
blood cells would carry the foreign cDNA for weeks, proving
that the murine hematopoietic stem cell, despite its very low
rate of division, could be so transduced. But the percentage
of infected cells was very low and expression of the
transferred gene was vestigial. The results suggested that
successful gene transfer with cDNAs borne on replication-
defective retroviruses would require high recombinant viral
titer, cell culture systems that would encourage stem cell
division without differentiation, and a setting in which target
cells would have a selective advantage following gene
transfer. The latter requirement proved to be an Achilles
heel.
The entire field of gene therapy was energized by the
findings of Williams and Dick and their colleagues [9,10],
but the barriers to translation and clinical application were
soon found to be almost insurmountable. The low level of
gene transfer and expression was extremely discouraging.
The slow pace prompted Orkin and Motulsky [11] to lower
their expectations for immediate clinical application, and
focus instead on solving the basic technical and biological
problems. In an attempt to gain some clinical traction,
Blaese and his colleagues [12] introduced retroviral cDNA ex
vivo into the mature T cells of patients with
immunodeficiency due to mutations in adenosine
deaminase. They used a modified retrovirus bearing a
normal adenosine deaminase cDNA. The treatment provided
little if any clinical benefit, and the risk of malignancy was
obviously high because the T cells were influenced to divide
in culture in order to enhance transduction. The approach
was soon abandoned.
Concerns about unwieldy and potentially unsafe clinical
research protocols began to mount in the United States.
Four levels of review, the Recombinant DNA Advisory
Committee, individual institutional review boards,
individual institutional biosafety committees, and the Food
and Drug Administration all established barriers that slowed
the pace of gene therapy clinical research to a crawl. This
necessary regulatory environment was onerous enough, but
it became even more obstructive when investigators at the
University of Pennsylvania performed a study of gene
replacement in a rare metabolic disorder using adenovirus
as a vector in order to infect non-dividing liver cells. One
young adult with the disease died after a high titer of virus
was administered [13]. An investigation revealed that the
gene therapists had a financial stake in the company that
produced the vector. That revelation initiated an even higher
burden of regulation and added massively to a growing
concern about conflict of interest in clinical research - a
conflict that continues to roil academic waters to this day.
Meanwhile, after four decades of development, the clinical
application of allogeneic hematopoietic stem cells in
transplantation for the treatment of congenital bone marrow
diseases was moving ahead reasonably briskly (sans gigantic
regulatory hurdles). This form of cell-based therapy, though
initially applicable in only the 25-30% of patients with
histocompatible donors, was associated with success in
several patients with severe immunodeficiencies, congenital
bone marrow failures of several types and even the inherited
hemoglobin disorders [14]. Increasing success was also
being reported with matched unrelated stem cell donors
[15]. Clearly, gene therapy application lagged well behind
hematopoietic stem cell treatment.
After the unfortunate event in Philadelphia, the field
moldered along. Adenovirus vectors were thought to be too
immunogenic to be useful but they and their cousin, the tiny
adeno-associated virus, were considered to be worthy of
evaluation in the transduction of non-dividing cells such as
liver cells or endothelial cells. Indeed, High and her co-
workers [16] have made quiet progress in the correction of
canine hemophilia with adeno-associated virus. But immune
responses to adeno-associated virus remain a problem. Most
groups interested in hematopoietic targets or cancer vaccine
protocols continue to focus on defective murine leukemia
viruses or lentiviruses. The latter are thought to have a
higher capacity than murine leukemia viruses to integrate
within the DNA of non-dividing cells. The differences may be
less striking than originally believed.
From 1985 to 2002 there was little or no progress in the
United States and elsewhere. Bright young clinical
investigators were gently urged to direct their energies
elsewhere. Both the science and the regulatory apparatus
seemed to be daunting, and the funding was fragmented and
difficult to obtain. But in 2002 Cavazzana-Calvo and his
colleagues [17] blew new life into the field when they made
the startling announcement that they had successfully
treated nine of ten patients with X-linked severe combined
immunodeficiency (SCID), utilizing a fairly standard murine
leukemia viral vector that carried the common gamma chain
of the interleukin-2 receptor into autologous bone marrow
cells. Thrasher and his colleagues [18] subsequently
confirmed these results in another study. Shortly thereafter,
however, cynicism returned when the authors reported that
several of the patients had developed T cell leukemia.
Careful work by the investigators revealed that the long
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for the LMO2 proto-oncogene on chromosome 11 [19,20].
But even random integration of the LTR at the LMO2 site
would favor selection of such cells. The LMO2 proto-
oncogene is often activated by translocation (11:14) in T cell
leukemia. Clearly, the gene-corrected immunocytes had a
survival advantage, but the malignant T cells had an even
greater survival advantage as well as a growth advantage.
What was once a promising new start for gene therapy
became an enormous set-back. Vector safety had always
been a pressing issue - now it had become a yawning chasm:
of 20 patients with X-linked SCID treated by gene transfer in
these two trials, 18 are currently alive and with good
immune reconstitution, but five have experienced a serious
side-effect. Of these five children, one died of therapy-
related leukemia, and one died of complications of a
subsequent stem cell transplant that was performed as a
result of the failure of gene therapy. The others are in
remission.
Of further concern have been the results of retroviral
correction of oxidase deficiency in chronic granulomatous
disease. In two well-described cases, correction of
granulocyte oxidase deficiency has been achieved but at the
cost of clonal proliferation of cells activated at the sites of the
MDS-1-EVI1, PRDM16 or SETBP1 proto-oncogenes [21].
This result represents a clear leukemogenic hazard.
Furthermore, other in vitro studies have demonstrated
similar insertions by lentiviruses bearing beta globin genes.
Finally, Williams and his co-workers [22] have temporarily
discontinued their pioneering work on the correction of the
deficiency of DNA repair pathways in hematopoietic stem
cells of patients with Fanconi anemia, because they are
concerned that current vectors that permit rescue of those
cells may induce insertional mutagenesis and leukemia in
the treated patients, and that focus should be on developing
methods of expanding deficient hematopoietic stem cells in
this disease.
Despite these serious setbacks there have been some recent
bright lights. In 2008, Maguire [23] and Bainbridge [24] and
their colleagues reported progress on the treatment of
Leber's optic atrophy with an adeno-associated viral vector
applied to the retina. And retrovirally transfected epidermal
stem cells have been grown into keratinocytes to correct the
lesions of epidermolysis bullosum [25]. More follow-up is
needed but the initial results hold promise for local
applications of gene transfer. An encouraging report
emerged at a recent annual meeting of the European Society
of Gene and Cell Therapy. Lentivirus vectors have been used
to transduce hematopoietic stem cells in X-linked
adrenoleukodystrophy, a progressive demyelinating disease
that causes severe debilitation by early teenage years. Long-
term and stable gene modification has been observed in 20%
of myeloid cells, well within the range to reverse phenotypes
in some red cell and myeloid disorders. Finally, Auiti and his
colleagues have recently reported highly encouraging results
in the treatment of adenosine deaminase deficiency [26,27]. 
Thus, gene therapy of hematopoietic diseases with
retroviruses lumbers in choppy straits twixt the Scylla of
insufficient gene transfer and the Charybdis of leukemia,
while the therapy of metabolic and coagulation disorders
with adeno- and adeno-associated viruses is blunted by
immune reponses to the vectors. To committed gene
therapists, these are simply the challenges that they have
always faced, while those who are engaged in stem cell
transplantation, or in finding better halfway measures that
support afflicted patients, work as best they can, all the
while hoping that the holy grail of gene replacement will
one day become a safe reality. The future could lie in the
promising field of site-specific gene correction using
modified nucleases [28], and the conversion of corrected
somatic cells such as fibroblasts to functioning
hematopoietic stem cells [29]. Time will tell.
A Ab bb br re ev vi ia at ti io on ns s
cDNA, copy DNA; LTR, long terminal repeat; SCID, severe
combined immunodeficiency.
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